Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Tech Primed to Play Key Role in Cancer Drug Development Efforts
Predictive Oncology subsidiary TumorGenesis developing faster, less costly, and more accurate PDx cancer models that better mimic the patient's tumor TumorGenesis revolutionary technology will provide pharmaceuticals with quicker and more effective drug development while significantly improving patient outcomes There’s an unmet need for a multi-omic approach (genome, transcriptome, epigenome, proteome, responseome, and microbiome), but such data is difficult to generate quickly. Predictive Oncology has access to historical data that competitors need at least five years to develop, which presents a multi-million-dollar market opportunity The global cancer diagnostics market was valued at $144.4 billion in 2018 and is expected to grow…